Ionis Pharmaceuticals Presents Positive Long-Term Data for Olezarsen in Severe Hypertriglyceridemia

Details

presented positive new data from the open-label extension study of CORE and CORE2 evaluating olezarsen in people with severe hypertriglyceridemia during the National Lipid Association Scientific Sessions in Chicago. The study, which included 53 patients who completed 12 months of treatment, showed that mean hepatic fat fraction levels returned toward baseline after 24 months of treatment with the 80 mg dose of olezarsen. The treatment also demonstrated a favorable safety profile and high patient retention. These results suggest that olezarsen may be effective in managing severe hypertriglyceridemia over the long term.

Items reported

About Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.